As the CDK7 inhibitor SY-1365 is currently in clinical trials in cancer patients [https://clinicaltrials.gov/ct2/show/NCT03134638] and the HDAC inhibitor panobinostat is currently in clinical practice, our findings identify CDK7 inhibitor and HDAC inhibitor combination therapy as a treatment strategy for neuroblastoma. The gene discussed is HDAC9; the disease is cancer.